Resource • Article
Biorasi Welcomes Scott Nenninger as Chief Financial Officer
Miami, FL (July 7, 2020) – Biorasi, a leading global full-service contract research organization (CRO), is proud to announce the appointment of Scott Nenninger to the position of Chief Financial Officer (CFO). Beginning July 2020, Scott will provide leadership and oversight in corporate and operational finance, investor relations, and strategic analysis.
“Scott is an important addition to our leadership team who brings critical skills that enable businesses to scale,” said Chris O’Brien, CEO of Biorasi. “He is adept at implementing comprehensive financial and decision-making processes to optimize resource allocation and enable strategic and operational decisions. This will allow us to continue to maintain world class clinical trial effectiveness and efficiency for our sponsors as we continue to scale our business.”
In his new role at Biorasi, Scott brings with him broad financial and executive leadership skills developed at large, publicly traded companies including Experian, Nielsen and Dun & Bradstreet. Most recently, Scott held the position of CFO for Clarity Insights, a mid-tier data and analytics consultancy owned by Biorasi’s private equity sponsor.
“I chose to join Biorasi because I believe that its people, leadership, and culture position the company for extraordinary growth,” said Scott. “As CFO, I plan to focus on efforts that enable the business to accelerate in its evolution – both as a leader and an innovator in the CRO industry.”
Biorasi is a customer-focused, full-service, contract research organization (CRO) that optimizes the design and delivery of clinical trials for its sponsors, powered by our proprietary TALOS™ project management system. Pharmaceutical companies around the globe rely on Biorasi to consistently deliver success in clinical trial programs for rare and orphan disease and other hard to recruit patient populations such as precision medicine, as well as successful clinical trial rescue. Biorasi’s expertise includes a wide range of molecule types, therapeutic areas, and regulatory pathways. Biorasi is a leader in neurology, nephrology, dermatology, oncology, and the emerging digital therapeutics market.
Established in 2002, Biorasi is headquartered in Miami, FL, with office-based teams around the globe. From its regional presences, Biorasi is able to directly support studies in the Americas, Europe, and APAC. The company has received the coveted CRO Leadership Award from Life Science Leader magazine and has been placed on the INC 500 list of fastest-growing companies in America.
To learn more about Biorasi’s mission and vision, including our full spectrum of decentralized clinical trials, explore our solutions on our website or contact us at firstname.lastname@example.org or (786) 388-0700